TYK2 and dermatomyositis: Future development of non-selective Tyk2 inhibitors will be focused on diseases where therapeutic benefit outweighs potential safety concerns, as illustrated by the current indications pursued for brepocitinib (SLE, dermatomyositis, and uveitis).